CNS Neuroscience & Therapeutics [Neurosurgery Wiki]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
====== CNS Neuroscience & Therapeutics ======

===== 📊 Overview & Metrics =====

  * **Name**: CNS Neuroscience & Therapeutics
  * **Publisher**: Wiley‑Blackwell
  * **Founded**: 1995 (as *CNS Drug Reviews*), rebranded in 2008
  * **Frequency**: Bimonthly
  * **Scope**: Clinical, experimental, and translational neuroscience
  * **Indexing**: SCIE, Scopus, DOAJ, PubMed Central
  * **Impact Factor (JCR 2021)**: 7.035
  * **Estimated Impact Factor (2023–2024)**: ~4.8
  * **Scopus Impact Score**: ~5.6
  * **H-index**: ~99
  * **SJR**: ~1.67
  * **Quartile**: Q1 in Neuroscience, Pharmacology, Psychiatry

**→ Summary**: A well-regarded mid-to-high-tier journal with strong indexing and influence in translational neuroscience.

===== 👍 Strengths =====

  * **Top Quartile Rankings** in multiple domains (Neuroscience, Psychiatry, Pharmacology)
  * **Broad Translational Scope**: From bench to bedside
  * **Reasonable Review Times**: ~4–6 weeks to first decision
  * **Rigorous Peer Review**: Thoughtful and constructive feedback
  * **Hybrid Open Access**: Optional OA publication with some APC waivers

===== ⚠️ Limitations =====

  * **Impact Factor Decline**: Dropped from 7.0 (2021) to ~4.8 (2023)
  * **Moderate Selectivity**: Acceptance rate around 25%
  * **Not Fully Open Access**: Hybrid model may limit visibility
  * **Average Author Experience**: Rated ~3/5 on SciRev

===== 🔍 Comparison with Peers =====

  * **Vs. Neuroscience & Biobehavioral Reviews**: Higher impact but narrower in scope
  * **Vs. Psychiatry & Clinical Neurosciences**: More clinically grounded, higher impact
  * **Vs. Nature Neuroscience / Neuron**: Lower impact, but faster and more accessible

===== 🧭 Suitability =====

**Ideal for**:
  * Translational neuroscience studies
  * Therapeutic trials or drug mechanism research
  * Authors seeking Q1 visibility with moderate speed

**Less ideal for**:
  * High-impact basic science without therapeutic focus
  * Work aiming for top-tier journals in basic neurobiology

===== ✔️ Final Verdict =====

*CNS Neuroscience & Therapeutics* is a solid, Q1-ranked journal ideal for translational neuroscience with therapeutic implications. It offers respectable impact, rigorous review, and broad indexing—though not suitable for breakthrough basic science aiming for elite impact.